TRCT
SABS icon

Tower Research Capital (TRC)’s SAB Biotherapeutics SABS Stock Holding History

Tower Research Capital (TRC)’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.83K Sell
2,520
-749
-23% -$2.79K ﹤0.01% 4007
2026
Q1 		$12.5K Buy
+3,269
New +$13K ﹤0.01% 3786
2025
Q4 		– Sell
-1,560
Closed -$3.14K – 5526
2025
Q3 		$3.14K Buy
1,560
+834
+115% +$1.89K ﹤0.01% 4542
2025
Q2 		$1.27K Buy
726
+692
+2,035% +$1.15K ﹤0.01% 4837
2025
Q1 		$46 Sell
34
-808
-96% -$1.85K ﹤0.01% 5079
2024
Q4 		$3.19K Sell
842
-1,243
-60% -$4.08K ﹤0.01% 4693
2024
Q3 		$5.63K Sell
2,085
-308
-13% -$853 ﹤0.01% 4240
2024
Q2 		$7.42K Buy
2,393
+957
+67% +$3.51K ﹤0.01% 4468
2024
Q1 		$6.52K Sell
1,436
-88
-6% -$485 ﹤0.01% 4356
2023
Q4 		$10.5K Buy
1,524
+30
+2% +$252 ﹤0.01% 4240
2023
Q3 		$9.41K Buy
1,494
+39
+3% +$287 ﹤0.01% 4222
2023
Q2 		$12.1K Sell
1,455
-151
-9% -$1.24K ﹤0.01% 3905
2023
Q1 		$7K Buy
1,606
+465
+41% +$2.94K ﹤0.01% 4763
2022
Q4 		$7K Sell
1,141
-223
-16% -$2.04K ﹤0.01% 4613
2022
Q3 		$10K Buy
1,364
+546
+67% +$5.42K ﹤0.01% 4570
2022
Q2 		$12K Buy
818
+645
+373% +$13.5K ﹤0.01% 4305
2022
Q1 		$7K Buy
173
+16
+10% +$739 ﹤0.01% 4756
2021
Q4 		$12K Buy
+157
New +$14.7K ﹤0.01% 4322
2021
Q3 		– Sell
-9
Closed -$1K – 6117
2021
Q2 		$1K Buy
+9
New +$893 ﹤0.01% 5248

Other funds holding SABS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tower Research Capital (TRC)'s SABS Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its SAB Biotherapeutics (SABS) stake by 23% in Q2 2026, selling an estimated $2.79K and leaving 2,520 shares worth $9.83K. The position accounts for ﹤0.01% of the portfolio, ranked #4007.

Tower Research Capital (TRC) first reported a position in SABS in Q2 2021 and has held it in 19 quarters since. The position peaked at $12.5K in Q1 2026. 46 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Tower Research Capital (TRC) held 2,520 shares of SAB Biotherapeutics worth $9.83K as of Q2 2026.
  • Tower Research Capital (TRC) sold 749 SAB Biotherapeutics shares in Q2 2026, an estimated $2.79K.
  • SAB Biotherapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4007 holding.
  • Tower Research Capital (TRC) first reported a position in SAB Biotherapeutics in Q2 2021 and has held it in 19 quarters since.
  • Tower Research Capital (TRC)'s SAB Biotherapeutics position peaked at $12.5K in Q1 2026.
  • 46 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.